For its first fiscal quarter (ending March 31), CVS Health Corp (NYSE: CVS) has reported a -47% decline in E.P.S. from $1.66 a year ago to $0.88 in the current quarter. Relative to the consensus estimate of $2.00, this was a shortfall of $-1.12. For the latest four quarters through March 31, E.P.S. were $5.71 versus $3.16 for the same period a year ago — an increase of 81%.
Recent Price Action
CVS Health Corp (NYSE: CVS) stock closed at $56.31 on 5/1/24 after a major decline of -16.8%. Moreover, trading volume in this decline was exceptionally high at 671% of normal. The stock has declined -17.8% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CVS is expected to continue to be a major Value Builder.
CVS Health has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. CVS Health has a very high Appreciation Score of 88 but a neutral Power Rating of 47, with the Positive Value Trend Rating the result.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment